EUVIMEDEUVIMED entdecken
Übersichtsarbeit

TET2 ‐ CHIP : From Mutation to Malady

Heng Jian iD, Mingyang Sun, Xinyi Xia, Chengke Su, Kai Su, Jiahao Xu, Yuanfan Yuan, Chenxi Li, Miao Yu, Xiang Cheng

The FASEB Journal · 31.05.2026 · 40 (10)

DOI: 10.1096/fj.202600383r ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The FASEB Journal, online erschienen am 26.05.2026. Verfasst von Heng Jian und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China. Hauptthemen laut MEDLINE: DNA-Binding Proteins, Clonal Hematopoiesis, Proto-Oncogene Proteins, Mutation. Die Arbeit nennt 158 Literaturangaben. Gefördert von: The Noncommunicable Chronic Diseases-National Science and Technology Major Project, Hubei Technology Innovation Project, Key Research and Development Program of Wuhan.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Somatic mutations in hematopoietic cells can drive clonal expansion without overt malignancy, a condition defined as clonal hematopoiesis of intermediate potential (CHIP). Among CHIP driver genes, TET2 is notable for its high prevalence and strong association with cardiovascular disease (CVD) and chronic inflammation. TET2 encodes a methylcytosine dioxygenase essential for epigenetic regulation, and its loss impairs hematopoietic stem cell differentiation while altering the functions of mature myeloid and lymphoid cells. Aging‐related inflammation, along with lifestyle exposures, metabolic disorders, cancer therapy, and HIV infection, affects the emergence and expansion of TET2 ‐mutant clones. Recently, evidence increasingly links TET2 ‐CHIP to the incidence and prognosis of diverse CVDs. Emerging studies also suggest potential therapeutic strategies for TET2 ‐CHIP–associated cardiovascular disease. This review summarizes current understanding of TET2 biology, mechanisms of TET2 ‐CHIP development, and its cardiovascular implications.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DNA-Binding ProteinsClonal HematopoiesisProto-Oncogene ProteinsMutationCardiovascular DiseasesHumansDioxygenasesAnimals

Stichwörter der Autor:innen

TET2cardiovascular diseaseclonal hematopoiesis

Substanzen

DioxygenasesTET2 protein, humanDNA-Binding ProteinsProto-Oncogene Proteins

Autor:innen und Institutionen

  • Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Hubei Key Laboratory of Biological Targeted Therapy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Hubei Provincial Engineering Research Center of Immunological Diagnosis and Therapy for Cardiovascular Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
  • Key Laboratory of Biological Targeted Therapy (Huazhong University of Science and Technology), Ministry of Education, Wuhan, Hubei, China.

ORCID-Profile: Heng Jian

Förderung

  • The Noncommunicable Chronic Diseases-National Science and Technology Major Project
  • Hubei Technology Innovation Project
  • Key Research and Development Program of Wuhan
  • National Natural Science Foundation of China

Zitieren

APA

Jian, H., Sun, M., Xia, X., Su, C., Su, K., Xu, J., Yuan, Y., Li, C., Yu, M., & Cheng, X. (2026). TET2 ‐ CHIP : From Mutation to Malady. The FASEB Journal, 40(10). https://doi.org/10.1096/fj.202600383r

Vancouver

Jian H, Sun M, Xia X, Su C, Su K, Xu J, et al. TET2 ‐ CHIP : From Mutation to Malady. The FASEB Journal. 2026;40(10). doi:10.1096/fj.202600383r

BibTeX
@article{Jian2026,
  author = {Jian, Heng and Sun, Mingyang and Xia, Xinyi and Su, Chengke and Su, Kai and Xu, Jiahao and Yuan, Yuanfan and Li, Chenxi and Yu, Miao and Cheng, Xiang},
  title = {TET2 ‐ CHIP : From Mutation to Malady},
  journal = {The FASEB Journal},
  year = {2026},
  volume = {40},
  number = {10},
  doi = {10.1096/fj.202600383r}
}
Kostenlos starten →